Target's General Information
Target ID T83145
Target Name Nuclear factor NF-kappa-B (NFKB)
Synonyms Nuclear factor of kappa light polypeptide gene enhancer in B-cells; DNA-binding factor KBF
Target Type Successful
Gene Name NFKB1; NFKB2; RELA; RELB; REL
UniProt ID NFKB1_HUMAN||NFKB2_HUMAN||TF65_HUMAN||TF65_MOUSE
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Atopic dermatitis
Example drug P-1 Discontinued in Phase 3 [1], [2], [3]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.54
Z-score: 2.85
P-value: 7.38E-10
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Myeloma
Example drug AS602868 Discontinued in Phase 1 [2], [3], [4]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.02
Z-score: 0.08
P-value: 7.23E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug Sulfasalizine Phase 3 [2], [3], [5]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.84
Z-score: 3.94
P-value: 7.34E-09
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Asthma
Example drug MOL-218 Terminated [2], [3], [6]
Tissue Nasal and bronchial airway
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.2
Z-score: -0.39
P-value: 7.89E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Acute myelocytic leukemia
Example drug LC-1 Phase 1 [2], [3], [7]
Tissue Bone marrow
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.16
Z-score: 0.27
P-value: 5.39E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Liver failure
Tissue Liver tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.22
Z-score: 0.64
P-value: 3.14E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Multiple sclerosis
Tissue Spinal cord
Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section Fold-change: -0.06
Z-score: -0.47
P-value: 9.69E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006996)
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
REF 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941)
REF 5 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
REF 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009549)
REF 7 A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.